Results 61 to 70 of about 140,776 (178)

Successful management of bullous pemphigoid with dimethyl fumarate therapy: A case report

International Journal of Women's Dermatology, 2019
A 69-year-old woman affected by multiple sclerosis for 35 years was diagnosed with bullous pemphigoid (BP) and treated successfully with dimethyl fumarate (DMF) at a dose of 120 mg twice per day for 7 days and then increased to 240 mg twice per day after
Aslı Bilgic-Temel, MD, Shilpa Das, MD, Dedee F. Murrell, MA, BMBCh, FAAD, MD, FACD FRCP   +2 more
doaj   +1 more source

Dimethyl Fumarate Treatment in Patients with Moderate-to-Severe Psoriasis: A 52-week Real-life Study

Acta Dermato-Venereologica, 2023
is missing (Short communication)
Laura Gnesotto, Guido Mioso, Federico Bardazzi, Federica Filippi, Vito Di Lernia, Alberico Motolese, Sergio Di Nuzzo, Andrea Conti, Federica Arginelli, Monica Corazza, Giulia Odorici, Alessandro Borghi, Paolo Gisondi, Luigi Naldi, Paolo Dapavo, Aurora Parodi, Martina Burlando, Stefano Piaserico   +17 more
doaj   +1 more source

Engineered Cyanobacteria‐Hydrogel Microecological System for Oxygen Reprogramming Synergizes Immunomodulation With Anabolism in Osteoarthritis Therapy

Advanced Science, EarlyView.
An injectable cyanobacteria‐laden hydrogel enables light‐dependent oxygen metabolism engineering for osteoarthritis therapy. Photosynthetic oxygen release under red light irradiation suppresses synovial inflammation via HIF‐1α inhibition and M2 macrophage polarization, while respiratory oxygen consumption in darkness stabilizes chondrocyte HIF‐1α to ...
Lerong Yang, Chong Shen, Hongjun Huang, Siyi Liu, Zeyu Huang, Licheng Xi, Huan Cao, Li Zheng, Zainen Qin   +8 more
wiley   +1 more source

Atypical Multiple Sclerosis Lesions or Progressive Multifocal Leukoencephalopathy Lesions: That Is the Question

Journal of Investigative Medicine High Impact Case Reports, 2020
Progressive multifocal leukoencephalopathy (PML) is a serious infective disease of the central nervous system that may occur in case of severe immunosuppression or after some treatment for multiple sclerosis (MS) with natalizumab, dimethyl fumarate, and ...
Stefania Federica De Mercanti MD, PhD, Dario Gned MD, Manuela Matta MD, Marco Iudicello MD, Emanuele Franchin MD, Marinella Clerico MD, PhD   +5 more
doaj   +1 more source

The Cancer Cell Metabolic Reprogramming Remodels the Tumor Microenvironment: Molecular Mechanisms and Therapeutic Strategies

Advanced Science, EarlyView.
This review elucidates how cancer cell metabolic reprogramming—across glucose, lipid, amino acid, and nucleotide pathways—remodels the tumor microenvironment to suppress anti‐tumor immunity and promote immune escape. Targeting these metabolic axes offers promising strategies to overcome immunotherapy resistance and enhance cancer treatment.
Guoqing Xiang, Zhicheng Zhou, Xue Jiang, Zhenguang Du, Yangyang Zhan, Xinli Liu   +5 more
wiley   +1 more source

Enhanced and complementary benefits of a nalfurafine and fingolimod combination to treat immune‐driven demyelination

Clinical & Translational Immunology, 2023
Objectives Multiple sclerosis (MS) is a neurodegenerative disease characterised by inflammation and damage to myelin sheaths. While all current disease‐modifying treatments (DMTs) are very effective at reducing relapses, they do not slow the progression ...
Katharina Robichon, Rabia Bibi, Mackenzie Kiernan, Lisa Denny, Thomas E Prisinzano, Bronwyn M Kivell, Anne Camille La Flamme   +6 more
doaj   +1 more source

Bioenergetic Materials for Tissue Regeneration: Modulating Metabolism to Promote Cellular Anabolism

Advanced Science, EarlyView.
Bioenergetic materials (BEMs) modulate cellular metabolism to promote tissue regeneration. Their principal mechanisms of action include metabolic substrate supplementation, metabolic enzyme modulation, organelle transfer, electrical current regulation, redox homeostasis modulation, and oxygen tension modulation.
Yuchen He, Yuwen Wang, Jonathan F. Gong, Yiting Lei, Fei Jin, Weihong Zhu, Rocky S. Tuan, Zhong Alan Li   +7 more
wiley   +1 more source

Bioequivalence of tegomil fumarate gastro-resistant capsules versus dimethyl fumarate gastro-resistant capsules under different fed conditions: two randomized, crossover, phase I studies

Frontiers in Neurology
ObjectiveTegomil fumarate is a newly approved treatment for relapsing–remitting multiple sclerosis. Two phase I studies were performed under different fed conditions to evaluate the bioequivalence and tolerability of tegomil fumarate versus dimethyl ...
Katja Zietz, Simona Rizea Savu, Lina Remis, Natalia Nicolau, Adriana Iordachescu, Florian Herb   +5 more
doaj   +1 more source

Glutaminolysis Blockade‐Empowered Bimodal Nanodepot for Spatially Complementary Sono‐Thermal Ablation via PANoptosis and STING Activation Against Large Tumors

Advanced Science, EarlyView.
An injectable bimodal TCPD nanodepot disrupts glutaminolysis and TCA metabolism, sensitizing large tumors to spatially complementary sono‐thermal ablation for complete treatment coverage. This intervention induces mitochondrial and endoplasmic reticulum dysfunction, genotoxicity, and NAD+ depletion, converging to trigger PANoptosome assembly and ...
Yi‐Ming Liu, Juan Qin, Si‐Yuan Wu, Xue‐Zhen Zhu, Yun‐Fei Cai, Pei‐Yao Sun, Hao Yang, Xing‐Yue Wang, Shu Li, Duo Wang, Hai‐Dong Zhu   +10 more
wiley   +1 more source

Assessment of Total Side Effects of Oral Agents for the Treatment of Relapsing–Remitting Multiple Sclerosis Patients in Imam Khomeini Clinic in Hamadan [PDF]

Armaghane Danesh Bimonthly Journal, 2023
Background & aim: Three oral drugs, including fingolimod, dimethyl fumarate, and teriflunomide, which are clinically approved for the therapy of relapsing–remitting multiple sclerosis (RRMS) were reviewed in this work.
M Ghiasian, N Lashkari, M Mohammadi, Y Mohammadi, M Soleimani, R Mahjub, S Ataei   +6 more
doaj